{{Drugbox
| IUPAC_name = ''N''-(2-aminoethyl)-5-chloro-pyridine-2-carboxamide
| image = Lazabemide.svg

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Development terminated
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 6640
| CAS_number = 103878-84-8
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 71307
| ChemSpiderID = 64426
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 420HD787N9
| KEGG = D04681

<!--Chemical data-->
| C=8 | H=10 | Cl=1 | N=3 | O=1 
| molecular_weight = 199.64 g/mol
}}

'''Lazabemide''' (proposed trade names '''Pakio''', '''Tempium''') is a [[reversible inhibition|reversible]] and [[binding selectivity|selective]] [[monoamine oxidase inhibitor|inhibitor]] of [[monoamine oxidase B]] (MAO-B) that was under development as an [[antiparkinsonian]] agent but was never marketed.<ref name="pmid7931245">{{cite journal |vauthors=Henriot S, Kuhn C, Kettler R, Da Prada M | title = Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings. | journal = J Neural Transm Suppl. | volume = 41 | pages = 321â€“325 | year = 1994 | pmid = 7931245 }}</ref>

== References ==
{{Reflist}}

{{Antiparkinsonian}}
{{Monoamine metabolism modulators}}

[[Category:Abandoned drugs]]
[[Category:Monoamine oxidase inhibitors]]
[[Category:Chloroarenes]]
[[Category:Pyridines]]
[[Category:Carboxamides]]

{{nervous-system-drug-stub}}